Mar. 20, 2020-- Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, has been monitoring the development of the novel coronavirus (COVID-19) outbreak using our resources in conjunction with the appropriate global health and security agencies. The company’s top priority is to protect the health and well-being of its employees and their families as well as to ensure the continuity of its operations so it can continue to provide access to medicines for patients in need.
After review of its end-to-end supply chain, including collaboration with our suppliers, at this time, Mallinckrodt anticipates no disruption to its manufacturing and/or distribution capabilities resulting from the novel coronavirus (COVID-19) situation. The company is keeping this evolving situation under review.
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTS
This document includes forward-looking statements with regard to our ability to conduct business during the COVID-19 outbreak. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: natural disasters or other catastrophic events; complex manufacturing processes; satisfaction of regulatory and other requirements; changes in or failure to comply with relevant laws and regulations; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; issues with product quality, manufacturing or supply, or patient safety issues; and other risks identified and described in more detail in the "Risk Factors" section of Mallinckrodt's most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.